MTOR and neoplasm: Our findings demonstrate that activation level of S6 in tumor cells is prognostic of therapeutic response and could be relevant to explore the involvement of PI3K/Akt/mTOR targeting therapy to avoid or delay hormone independence and consequently endocrine resistance.